PriceTargets.com logo

GSK - GSK Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $43.25
  • Forecasted Upside: 28.72%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 7 Hold Ratings
  • 0 Buy Ratings
  • 3 Strong Buy Ratings
$33.60 As of 12/20/2024 06:40 PM ET
▲ +0.17 (0.51%)

This chart shows the closing price for GSK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New GSK Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GSK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GSK

Analyst Price Target is $43.25
▲ +28.72% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for GSK in the last 3 months. The average price target is $43.25, with a high forecast of $47.00 and a low forecast of $39.50. The average price target represents a 28.72% upside from the last price of $33.60.

This chart shows the closing price for GSK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 polled investment analysts is to moderate buy stock in GSK. This rating has held steady since August 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 3 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 4 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/25/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
6/23/2024
  • 3 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 3 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 3 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 3 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2024Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
11/12/2024Jefferies Financial GroupDowngradeBuy ➝ Hold$53.00 ➝ $39.50
10/31/2024GuggenheimDowngradeBuy ➝ Neutral
8/27/2024BarclaysUpgradeHold
8/7/2024ArgusUpgradeStrong-Buy
7/8/2024UBS GroupDowngradeBuy ➝ Neutral
7/2/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$52.50 ➝ $53.00
6/24/2024CitigroupUpgradeStrong-Buy
6/20/2024Berenberg BankUpgradeStrong-Buy
5/30/2024The Goldman Sachs GroupInitiated CoverageNeutral$47.00
3/4/2024GuggenheimUpgradeNeutral ➝ Buy
2/13/2024CitigroupUpgradeNeutral ➝ Buy
1/23/2024Morgan StanleyInitiated CoverageEqual Weight
1/3/2024Jefferies Financial GroupUpgradeHold ➝ Buy
7/14/2023HSBCInitiated CoverageReduce
3/17/2023Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
2/26/2023The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy
2/10/2023Berenberg BankBoost TargetGBX 1,580 ➝ GBX 1,730
2/2/2023JPMorgan Chase & Co.Boost TargetGBX 1,350 ➝ GBX 1,400
1/3/2023JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
12/8/2022AlphaValueUpgradeBuy
12/5/2022Bank of AmericaDowngradeNeutral ➝ Underperform
12/2/2022CitigroupLower TargetGBX 1,975 ➝ GBX 1,550
11/30/2022Morgan StanleyLower TargetGBX 1,650 ➝ GBX 1,535
11/11/2022UBS GroupDowngradeNeutral ➝ Sell
11/8/2022JPMorgan Chase & Co.Lower TargetGBX 1,900 ➝ GBX 1,600
10/14/2022BarclaysLower TargetGBX 1,800 ➝ GBX 1,450
10/12/2022Morgan StanleyBoost TargetGBX 1,550 ➝ GBX 1,650
9/29/2022Oddo BhfUpgradeNeutral ➝ Outperform
9/15/2022Credit Suisse GroupUpgradeUnderperform ➝ Neutral
9/8/2022Jefferies Financial GroupDowngradeBuy ➝ Hold
9/7/2022Deutsche Bank AktiengesellschaftLower TargetGBX 1,750 ➝ GBX 1,500
9/7/2022Morgan StanleyLower TargetGBX 1,860 ➝ GBX 1,550
8/5/2022Morgan StanleyReiterated RatingEqual Weight
7/21/2022CitigroupReiterated RatingNeutral
7/20/2022UBS GroupLower TargetGBX 1,876 ➝ GBX 1,850
7/19/2022AlphaValueDowngradeReduce
7/15/2022Credit Suisse GroupBoost TargetGBX 1,400 ➝ GBX 1,600
4/29/2022BarclaysBoost TargetGBX 1,775 ➝ GBX 1,800
4/28/2022JPMorgan Chase & Co.Boost TargetGBX 1,740 ➝ GBX 1,900
4/14/2022BarclaysBoost TargetGBX 1,675 ➝ GBX 1,775
2/28/2022Stifel NicolausInitiated CoverageHold
2/11/2022DZ BankDowngradeBuy ➝ Hold
11/24/2021Berenberg BankReiterated RatingBuy
11/8/2021UBS GroupReiterated RatingNeutral
11/5/2021BarclaysUpgradeUnderweight ➝ Equal Weight
11/3/2021Morgan StanleyReiterated RatingEqual Weight
11/1/2021JPMorgan Chase & Co.Reiterated RatingNeutral
10/28/2021BarclaysReiterated RatingUnderweight
10/18/2021Berenberg BankReiterated RatingBuy
10/7/2021Morgan StanleyReiterated RatingEqual Weight
9/20/2021UBS GroupReiterated RatingNeutral
8/26/2021UBS GroupReiterated RatingNeutral
8/20/2021JPMorgan Chase & Co.Reiterated RatingNeutral
8/19/2021Berenberg BankReiterated RatingBuy
8/3/2021UBS GroupReiterated RatingNeutral
7/19/2021BarclaysReiterated RatingUnderweight
7/6/2021Morgan StanleyReiterated RatingEqual Weight
7/1/2021UBS GroupReiterated RatingNeutral
6/24/2021Credit Suisse GroupReiterated RatingUnderperform
6/23/2021Deutsche Bank AktiengesellschaftUpgradeSell ➝ Hold
6/11/2021Deutsche Bank AktiengesellschaftReiterated RatingSell
6/2/2021Baader BankReiterated RatingBuy
5/11/2021UBS GroupReiterated RatingNeutral
4/30/2021Deutsche Bank AktiengesellschaftReiterated RatingSell
4/20/2021Morgan StanleyReiterated RatingEqual Weight
4/20/2021UBS GroupReiterated RatingNeutral
3/29/2021Leerink PartnersReiterated RatingOutperform ➝ Market Perform
3/23/2021Leerink PartnersDowngradeOutperform ➝ Market Perform
2/12/2021Morgan StanleyReiterated RatingEqual Weight
2/11/2021Berenberg BankReiterated RatingBuy
2/9/2021JPMorgan Chase & Co.Reiterated RatingNeutral
2/8/2021UBS GroupReiterated RatingNeutral
2/5/2021BarclaysReiterated RatingUnderweight
2/3/2021Deutsche Bank AktiengesellschaftDowngradeHold ➝ Sell
1/20/2021UBS GroupReiterated RatingNeutral
1/20/2021Credit Suisse GroupDowngradeNeutral ➝ Underperform
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageHold
12/16/2020DZ BankReiterated RatingBuy
12/8/2020JPMorgan Chase & Co.Reiterated RatingNeutral
12/3/2020UBS GroupDowngradeBuy ➝ Neutral
11/13/2020Morgan StanleyUpgradeUnderweight ➝ Equal Weight
11/2/2020Liberum CapitalUpgradeHold ➝ Buy
10/30/2020BarclaysReiterated RatingUnderweight
10/21/2020JPMorgan Chase & Co.Reiterated RatingNeutral
10/12/2020UBS GroupReiterated RatingBuy
10/9/2020Morgan StanleyReiterated RatingUnderweight
10/5/2020Credit Suisse GroupReiterated RatingNeutral
9/29/2020Berenberg BankInitiated CoverageBuy
9/23/2020Oddo BhfUpgradeNeutral ➝ Buy
9/18/2020Societe GeneraleReiterated RatingBuy
9/8/2020JPMorgan Chase & Co.Reiterated RatingNeutral
9/1/2020AlphaValueUpgradeBuy
9/1/2020Morgan StanleyReiterated RatingUnderweight
8/12/2020UBS GroupReiterated RatingBuy
5/14/2020UBS GroupReiterated RatingBuy
5/5/2020JPMorgan Chase & Co.Reiterated RatingNeutral
4/30/2020BarclaysReiterated RatingUnderweight
2/12/2020Shore CapitalDowngradeHold ➝ Sell
1/16/2020BarclaysDowngradeEqual Weight ➝ Underweight
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.74 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 39 very positive mentions
  • 30 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
Mentions as of
5/25/2024
  • 24 very positive mentions
  • 8 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 20 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 20 very positive mentions
  • 28 positive mentions
  • 10 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 26 very positive mentions
  • 21 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 30 very positive mentions
  • 9 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2024
  • 32 very positive mentions
  • 22 positive mentions
  • 10 negative mentions
  • 3 very negative mentions
Mentions as of
11/21/2024
  • 40 very positive mentions
  • 26 positive mentions
  • 4 negative mentions
  • 6 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 40 very positive mentions
  • 26 positive mentions
  • 4 negative mentions
  • 6 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

GSK logo
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Read More

Today's Range

Now: $33.60
Low: $33.04
High: $33.87

50 Day Range

MA: $35.65
Low: $33.35
High: $39.21

52 Week Range

Now: $33.60
Low: $32.83
High: $45.92

Volume

6,812,826 shs

Average Volume

4,166,597 shs

Market Capitalization

$69.64 billion

P/E Ratio

21.82

Dividend Yield

4.53%

Beta

0.64

Frequently Asked Questions

What sell-side analysts currently cover shares of GSK?

The following Wall Street sell-side analysts have issued reports on GSK in the last twelve months: Argus, Barclays PLC, Berenberg Bank, Citigroup Inc., Deutsche Bank Aktiengesellschaft, Guggenheim, Jefferies Financial Group Inc., Morgan Stanley, StockNews.com, The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for GSK.

What is the current price target for GSK?

0 Wall Street analysts have set twelve-month price targets for GSK in the last year. Their average twelve-month price target is $43.25, suggesting a possible upside of 28.7%. The Goldman Sachs Group, Inc. has the highest price target set, predicting GSK will reach $47.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $39.50 for GSK in the next year.
View the latest price targets for GSK.

What is the current consensus analyst rating for GSK?

GSK currently has 7 hold ratings and 3 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for GSK.

What other companies compete with GSK?

Other companies that are similar to GSK include AstraZeneca, Novartis, Sanofi, Takeda Pharmaceutical and BioNTech. Learn More about companies similar to GSK.

How do I contact GSK's investor relations team?

GSK's physical mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The pharmaceutical company's listed phone number is 442080475000 and its investor relations email address is [email protected]. The official website for GSK is www.gsk.com. Learn More about contacing GSK investor relations.